Pharma BD Deal Intelligence
A $1.15B multi-target peptide discovery pact with Janssen, but upfront and research funding were never disclosed, leaving the milestone ceiling as the only hard number in a deal whose value still rides on programs reaching the clinic.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Janssen joins a long list of big pharma partners betting on PeptiDream's macrocyclic peptide discovery platform, with $1.15B in milestone potential reflecting…
The deal continues PeptiDream's pattern of stacked discovery collaborations with global pharma; success ultimately depends on whether any program advances to…
PeptiDream shares jumped 19% on the Janssen deal announcement as investors viewed the latest big-pharma alliance as further validation of platform durability.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
PeptiDream entered a multi-target peptide discovery collaboration with Janssen worth up to $1.15B in preclinical, clinical and commercialization milestones plus undisclosed royalties. Janssen received development and commercialization rights plus an option to peptide-drug conjugate (PDC) applications. Targets cover metabolic and cardiovascular indications. Upfront and research funding undisclosed.
The collaboration spans broad metabolic (e.g., diabetes, obesity, NASH-related) and cardiovascular (e.g., heart failure, dyslipidemia) targets to be selected by Janssen. Specific targets and indications were not disclosed. Both target areas represent very large prevalent populations and competitive innovation arenas where macrocyclic peptides and peptide-drug conjugates offer differentiated drug-like properties versus small molecules and antibodies.
PeptiDream's Peptide Discovery Platform System (PDPS) competes against rival peptide discovery technologies including Bicycle Therapeutics' bicyclic peptides, Ra Pharmaceuticals' Extreme Diversity platform (acquired by UCB in 2020), Aileron's stapled peptides, Encycle/Ensemble Therapeutics, and antibody-based discovery players. PeptiDream had previously inked discovery alliances with Novartis, Bristol-Myers Squibb, AstraZeneca, Amgen, GlaxoSmithKline, and Eli Lilly, making the Janssen deal incremental rather than category-defining. The deal's structure—undisclosed upfront, $1.15B in milestones, royalties—mirrors typical platform-discovery economics where the discovery partner monetizes scale rather than per-program success. PeptiDream stock jumped ~19% on announcement to 6,250 yen, reflecting investor enthusiasm for the cumulative platform validation. In metabolic/cardiovascular specifically, Janssen has historically been a leaner player than its rivals (Lilly/Novo in obesity-diabetes; Novartis/Amgen in cardiovascular), and the collaboration represented an attempt to access novel macrocyclic peptide modalities for hard-to-drug GPCRs and protein-protein interactions. See https://www.biopharmadive.com/news/jj-taps-peptide-technology-in-115b-discovery-deal/440134/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc. (Johnson & Johnson) / PeptiDream Inc. (this deal) | 2017 | $1.1B | — |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2017 deals · Cardiovascular deals